In a case closed just 191 days after filing, Upsher-Smith Laboratories, LLC and Amta Labs Limited reached a resolution that resulted in the dismissal without prejudice of all claims and counterclaims in Case No. 1:24-cv-00058 before the Delaware District Court. The dispute centered on U.S. Patent No. US10363224B2, covering extended-release topiramate capsules, a formulation technology with significant commercial implications in the specialty pharmaceutical market. Chief Judge Gregory B. Williams retained jurisdiction to enforce the settlement agreement, signaling that the parties reached a negotiated resolution rather than litigating through a full merits determination.

For pharmaceutical patent practitioners and in-house IP teams operating in the generic drug space, this case underscores the speed with which Hatch-Waxman-adjacent disputes can resolve when the commercial stakes and patent validity risks are carefully weighed. The dismissal without prejudice — with each party bearing its own costs — is a common signature of a licensing or settlement arrangement, and the court’s retained jurisdiction clause adds an enforcement mechanism that preserves the agreement’s integrity. R&D teams developing competing extended-release formulations should treat this case as a live signal for ongoing FTO risk in the topiramate delivery technology space.

Case Overview

The Parties

The Patent at Issue

U.S. Patent No. US10363224B2 covers formulations and methods related to extended-release topiramate capsules, an anticonvulsant and migraine-prevention drug. The patent’s claims likely protect specific encapsulation technologies, release profiles, or dosing mechanisms that allow topiramate to be delivered over an extended period, improving patient compliance and therapeutic outcomes. This type of formulation patent is a critical asset in pharmaceutical lifecycle management, enabling branded manufacturers to extend market exclusivity beyond the active compound’s base patent.

• • US10363224B2

Legal Representation

Plaintiff Counsel: Lewis Brisbois Bisgaard & Smith LLP (lead: Andrew Ralli)
Defendant Counsel: Duane Morris, LLP (lead: Frederick R. Ball)

Litigation Timeline & Procedural History

The case was filed on January 17, 2024 in the District of Delaware — the preeminent venue for pharmaceutical patent litigation in the United States and the forum of choice for Hatch-Waxman disputes. Delaware’s experienced patent judiciary, predictable procedural rules, and established precedent on pharmaceutical IP make it a strategically favorable venue for branded drug companies seeking to enforce formulation patents against generic entrants. Chief Judge Gregory B. Williams presided at the first-instance (district court) level, meaning no appellate review was reached before the case concluded.

The case resolved in just 191 days — from filing on January 17, 2024 to closure on July 26, 2024 — a timeline consistent with an early settlement rather than prolonged litigation through claim construction or summary judgment. The basis of termination, a dismissal without prejudice and without costs to either party, strongly indicates that the parties negotiated a private agreement, likely a licensing arrangement or consent judgment governing market entry timing. The court’s explicit retention of jurisdiction to enforce the agreement’s terms and resolve future disputes is a standard judicial mechanism that gives the settlement the force of a court order, providing both parties enforceable protections going forward.

The Verdict & Legal Analysis

Outcome

The Delaware District Court dismissed all claims and counterclaims between Upsher-Smith Laboratories and Amta Labs Limited without prejudice and without costs, disbursements, or attorneys’ fees awarded to either party. No damages were assessed and no permanent injunction was entered on the merits, as the case did not reach a full adjudication of the infringement or validity issues raised. The court retained jurisdiction to enforce the underlying settlement agreement, indicating that the dismissal reflects a privately negotiated resolution rather than a substantive ruling on the patent’s validity or Amta Labs’ alleged infringement.

Verdict Cause Analysis

The infringement action’s resolution through dismissal without prejudice reflects several strategic and procedural factors common to pharmaceutical patent disputes of this nature:

• The dismissal without prejudice preserves Upsher-Smith’s right to refile infringement claims if Amta Labs breaches any agreed-upon market entry restrictions or licensing conditions contained in the underlying settlement agreement.
• The mutual waiver of costs and attorneys’ fees to either party suggests a balanced negotiated outcome, where neither side achieved a clear litigation victory sufficient to justify a fee-shifting award.
• The court’s retained jurisdiction clause transforms what would otherwise be a purely private contract into a court-enforceable order, allowing either party to seek contempt sanctions or injunctive relief for non-compliance without filing a new lawsuit.
• The 191-day resolution timeline indicates the dispute was likely resolved before substantive patent litigation milestones such as a Markman hearing or fact discovery completion, reducing litigation costs for both parties while achieving commercial certainty.

Legal Significance

1. 1. Because the case was dismissed without prejudice on settlement rather than decided on the merits, US10363224B2 emerges from this litigation with its validity and enforceability legally intact, preserving Upsher-Smith’s ability to assert it against other generic challengers without the handicap of adverse rulings.
2. 2. The structure of this resolution — court-retained jurisdiction over a private agreement — is a signal to other generic manufacturers that Upsher-Smith is willing to resolve disputes through negotiated arrangements, which may influence how future ANDA filers approach licensing discussions versus full litigation.
3. 3. The absence of any invalidation or non-infringement ruling means that the claims of US10363224B2 have not been subjected to judicial claim construction, leaving the patent’s scope legally undefined and potentially broader or narrower than competitors might assume when evaluating their own design-around strategies.

Strategic Takeaways

For Patent Attorneys:

• When filing pharmaceutical formulation patent suits in Delaware, early identification of the defendant’s litigation risk tolerance and commercial timeline is critical — this case demonstrates that well-timed settlement discussions can achieve client objectives without the cost and uncertainty of full Markman proceedings.
• The court’s retention of jurisdiction in the dismissal order provides a powerful enforcement tool; ensure that any settlement agreement filed with a court-retained-jurisdiction order includes specific, measurable compliance milestones to maximize enforceability.
• Because US10363224B2 was not subjected to claim construction or validity rulings, other defendants in future litigation involving this patent cannot rely on this case for collateral estoppel arguments — assess the patent’s claims fresh based on prosecution history and prior art.
• The dismissal without prejudice structure protects the plaintiff’s ability to refile; when representing branded pharmaceutical clients, always negotiate for this structure rather than dismissal with prejudice unless substantial consideration is received in exchange.

For IP Professionals:

• In-house teams at generic pharmaceutical companies should monitor the status of US10363224B2 at the USPTO — including any post-grant proceedings such as IPR petitions — as the patent’s intact legal status following this settlement makes it an ongoing blocking risk for extended-release topiramate pipeline products.
• The speed of this resolution suggests that Upsher-Smith’s IP enforcement strategy may favor early settlement over prolonged litigation; benchmark this case when building licensing negotiation frameworks for topiramate-related formulation patents in your competitive intelligence program.

For R&D Teams:

• R&D teams working on extended-release topiramate or related anticonvulsant formulations should conduct a claim-by-claim FTO analysis of US10363224B2 before committing to a specific encapsulation or release-profile technology, as the patent’s claims remain judicially untested and potentially broad.
• Consider designing extended-release formulations around alternative delivery mechanisms — such as different polymer matrices, bead technologies, or release-rate profiles — that fall clearly outside the scope of US10363224B2’s claims to reduce future litigation exposure when seeking FDA approval.